Skip to content

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02846896
Enrollment
501
Registered
2016-07-27
Start date
2015-12-31
Completion date
2017-03-31
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Biliary Cirrhosis

Brief summary

PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Interventions

None listed

Sponsors

Vifor Pharma
CollaboratorINDUSTRY
Intercept Pharmaceuticals
CollaboratorINDUSTRY
Fondazione Epatocentro Ticino
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* PBC patients living in Switzerland

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Prevalence of PBC in Switzerlandfrom 1.1.2005 until 31.12.2015

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026